03462nam 2200577Ia 450 99621707060331620230721033135.01-281-84052-197866118405250-470-69740-70-470-69741-5(CKB)1000000000551489(EBL)366846(SSID)ssj0000136162(PQKBManifestationID)11150469(PQKBTitleCode)TC0000136162(PQKBWorkID)10064010(PQKB)11282680(MiAaPQ)EBC366846(OCoLC)264703263(EXLCZ)99100000000055148920080305d2008 uy 0engur|n|---|||||txtccrDefining optimal immunotherapies for type 1 diabetes[electronic resource] /[editors: Gregory Bock and Jamie Goode]London Novartis Foundation20081 online resource (224 p.)Novartis Foundation symposium ;v. 292Description based upon print version of record.0-470-72325-4 Includes bibliographical references and index.Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetesCD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject indexThis book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.The book integrates information from human and animal studies.The book considers T1D within the broader context of autoimmune disease.The format contains several discussions, which address specific questions and providesNovartis Foundation symposium ;v. 292.DiabetesImmunotherapyCongressesDiabetesTreatmentCongressesDiabetesImmunotherapyDiabetesTreatment616.46206Novartis Foundation.MiAaPQMiAaPQMiAaPQBOOK996217070603316Defining optimal immunotherapies for type 1 diabetes3068900UNISA